Seek Returns logo

AZN vs. HSBC: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at AZN and HSBC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Both AZN and HSBC are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.

SymbolAZNHSBC
Company NameAstraZeneca PLCHSBC Holdings plc
CountryUnited KingdomUnited Kingdom
GICS SectorHealth CareFinancials
GICS IndustryPharmaceuticalsBanks
Market Capitalization265.62 billion USD246.55 billion USD
ExchangeNasdaqGSNYSE
Listing DateMay 12, 1993July 16, 1999
Security TypeADRADR

Historical Performance

This chart compares the performance of AZN and HSBC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

AZN vs. HSBC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolAZNHSBC
5-Day Price Return2.77%-0.08%
13-Week Price Return23.60%16.74%
26-Week Price Return12.18%18.91%
52-Week Price Return8.58%56.86%
Month-to-Date Return14.29%0.48%
Year-to-Date Return22.09%33.71%
10-Day Avg. Volume1.68M13.23M
3-Month Avg. Volume1.20M14.03M
3-Month Volatility31.04%15.91%
Beta1.231.56

Profitability

Return on Equity (TTM)

AZN

19.84%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.85%
Q1
5.40%
Min
-10.91%

AZN’s Return on Equity of 19.84% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.

HSBC

13.86%

Banks Industry

Max
25.40%
Q3
15.55%
Median
12.00%
Q1
8.98%
Min
-0.10%

HSBC’s Return on Equity of 13.86% is on par with the norm for the Banks industry, indicating its profitability relative to shareholder equity is typical for the sector.

AZN vs. HSBC: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Net Profit Margin (TTM)

AZN

14.68%

Pharmaceuticals Industry

Max
40.67%
Q3
19.07%
Median
12.31%
Q1
4.50%
Min
-9.91%

AZN’s Net Profit Margin of 14.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

HSBC

34.16%

Banks Industry

Max
54.20%
Q3
35.73%
Median
28.97%
Q1
22.56%
Min
6.98%

HSBC’s Net Profit Margin of 34.16% is aligned with the median group of its peers in the Banks industry. This indicates its ability to convert revenue into profit is typical for the sector.

AZN vs. HSBC: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Operating Profit Margin (TTM)

AZN

20.04%

Pharmaceuticals Industry

Max
45.78%
Q3
23.14%
Median
16.68%
Q1
7.98%
Min
-7.13%

AZN’s Operating Profit Margin of 20.04% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

HSBC

40.44%

Banks Industry

Max
63.35%
Q3
44.73%
Median
37.24%
Q1
28.25%
Min
12.28%

HSBC’s Operating Profit Margin of 40.44% is around the midpoint for the Banks industry, indicating that its efficiency in managing core business operations is typical for the sector.

AZN vs. HSBC: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Profitability at a Glance

SymbolAZNHSBC
Return on Equity (TTM)19.84%13.86%
Return on Assets (TTM)7.76%0.85%
Net Profit Margin (TTM)14.68%34.16%
Operating Profit Margin (TTM)20.04%40.44%
Gross Profit Margin (TTM)82.07%--

Financial Strength

Current Ratio (MRQ)

AZN

0.86

Pharmaceuticals Industry

Max
4.65
Q3
2.64
Median
1.85
Q1
1.26
Min
0.78

AZN’s Current Ratio of 0.86 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

HSBC

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

For the Banks industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

AZN vs. HSBC: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Banks industry benchmarks.

Debt-to-Equity Ratio (MRQ)

AZN

0.73

Pharmaceuticals Industry

Max
1.75
Q3
0.82
Median
0.35
Q1
0.13
Min
0.00

AZN’s Debt-to-Equity Ratio of 0.73 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

HSBC

1.91

Banks Industry

Max
5.78
Q3
2.66
Median
1.05
Q1
0.40
Min
0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Banks industry.

AZN vs. HSBC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Banks industry benchmarks.

Interest Coverage Ratio (TTM)

AZN

9.51

Pharmaceuticals Industry

Max
103.95
Q3
43.60
Median
9.83
Q1
2.37
Min
-42.71

AZN’s Interest Coverage Ratio of 9.51 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

HSBC

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Banks industry.

AZN vs. HSBC: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Financial Strength at a Glance

SymbolAZNHSBC
Current Ratio (MRQ)0.86--
Quick Ratio (MRQ)0.67--
Debt-to-Equity Ratio (MRQ)0.731.91
Interest Coverage Ratio (TTM)9.51--

Growth

Revenue Growth

AZN vs. HSBC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

AZN vs. HSBC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

AZN

1.86%

Pharmaceuticals Industry

Max
7.14%
Q3
3.45%
Median
2.17%
Q1
0.33%
Min
0.00%

AZN’s Dividend Yield of 1.86% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

HSBC

5.59%

Banks Industry

Max
11.03%
Q3
6.00%
Median
3.87%
Q1
2.41%
Min
0.00%

HSBC’s Dividend Yield of 5.59% is consistent with its peers in the Banks industry, providing a dividend return that is standard for its sector.

AZN vs. HSBC: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Dividend Payout Ratio (TTM)

AZN

59.51%

Pharmaceuticals Industry

Max
199.58%
Q3
97.17%
Median
53.47%
Q1
22.97%
Min
0.00%

AZN’s Dividend Payout Ratio of 59.51% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

HSBC

71.79%

Banks Industry

Max
134.24%
Q3
79.39%
Median
55.09%
Q1
36.09%
Min
0.00%

HSBC’s Dividend Payout Ratio of 71.79% is within the typical range for the Banks industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

AZN vs. HSBC: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Dividend at a Glance

SymbolAZNHSBC
Dividend Yield (TTM)1.86%5.59%
Dividend Payout Ratio (TTM)59.51%71.79%

Valuation

Price-to-Earnings Ratio (TTM)

AZN

32.06

Pharmaceuticals Industry

Max
45.19
Q3
27.91
Median
20.59
Q1
15.08
Min
3.79

A P/E Ratio of 32.06 places AZN in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

HSBC

9.26

Banks Industry

Max
22.69
Q3
13.75
Median
10.32
Q1
7.73
Min
2.59

HSBC’s P/E Ratio of 9.26 is within the middle range for the Banks industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

AZN vs. HSBC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Price-to-Sales Ratio (TTM)

AZN

4.71

Pharmaceuticals Industry

Max
8.87
Q3
4.56
Median
2.14
Q1
1.58
Min
0.11

AZN’s P/S Ratio of 4.71 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

HSBC

1.74

Banks Industry

Max
4.90
Q3
2.98
Median
2.24
Q1
1.59
Min
0.45

The P/S Ratio is often not a primary valuation tool in the Banks industry.

AZN vs. HSBC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Banks industry benchmarks.

Price-to-Book Ratio (MRQ)

AZN

4.71

Pharmaceuticals Industry

Max
9.78
Q3
4.99
Median
2.48
Q1
1.53
Min
0.59

AZN’s P/B Ratio of 4.71 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

HSBC

1.07

Banks Industry

Max
2.09
Q3
1.40
Median
1.11
Q1
0.86
Min
0.29

HSBC’s P/B Ratio of 1.07 is within the conventional range for the Banks industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

AZN vs. HSBC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Banks industry benchmarks.

Valuation at a Glance

SymbolAZNHSBC
Price-to-Earnings Ratio (TTM)32.069.26
Price-to-Sales Ratio (TTM)4.711.74
Price-to-Book Ratio (MRQ)4.711.07
Price-to-Free Cash Flow Ratio (TTM)32.495.11